# Phase III Study on HMPL-523 for Treatment of ITP

> **NCT05029635** · PHASE3 · COMPLETED · sponsor: **Hutchmed** · enrollment: 272 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** HMPL-523
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05029635
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2025-05-16
- **Final completion:** 2025-09-18
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029635, "Phase III Study on HMPL-523 for Treatment of ITP". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05029635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*